Netherlands· NL-8ca89fc38ddc
Tabrecta 200mg, filmomhulde tabletten
A medicinal product containing capmatinibdihydrochloride 1-water, registered in Netherlands by Novartis Europharm Limited.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CAPMATINIBDIHYDROCHLORIDE 1-WATER
- Manufacturer
- Novartis Europharm Limited
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1650
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Capmatinibdihydrochloride 1-water in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTABRECTANovartis Europharm Limited, Dublin
- FinlandTabrectaNovartis Europharm Limited
- SpainTABRECTA 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- IrelandTabrecta 200 mg film-coated tabletsNovartis Europharm Limited
- IcelandTabrectaNovartis Europharm Limited*
- NorwayTabrectaNovartis Europharm Limited
- PolandTabrectaNovartis Europharm Limited
- SwedenTabrecta 200 mg Filmdragerad tablettNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tabrecta
- Liechtenstein · Tabrecta
- Norway · Tabrecta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7bbe4039-14f1-48cc-a879-9d0cf3c0d057 GET /v1/drugs/7bbe4039-14f1-48cc-a879-9d0cf3c0d057?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128258",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSPOVIDON (E 1202)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"IJZEROXIDE GEEL (E 172)",
"MACROGOL 4000",
"MAGNESIUMSTEARAAT (E 470b)",
"MANNITOL (D-) (E 421)",
"NATRIUMLAURILSULFAAT",
"POVIDON K 30 (E 1201)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"CAPMATINIBDIHYDROCHLORIDE 1-WATER"
],
"leaflet_url": null,
"authorised_at": "2022/06/20",
"procedure_number": "EMEA/H/C/004845",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1650",
"additional_monitoring": "Y"
}See everything about capmatinibdihydrochloride 1-water.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.